Supplementary Table S2: Summary of noncompartmental pharmacokinetic parameters following intravenous infusion of LY3022855

		Geometric Mean (CV%)				
Dose	**1 mg/kg**	**1.25 mg/kg**		**100 mg**		**100 mg**
Regimen	**WK1245**	**Q2W**		**Q2W**		**QW**
Cycle	**1**	**1**		**1**		**1**
Day	**1**	**1**	**29**	**1**	**29**	**1**
N	6	12	6	4	2	6
C_{168h} (μg/mL)	2.87[a] (73)	3.92[b] (60)	2.92[c] (52)	(5.09, 10.8)[d]	(20.5, 2.46)	6.29[e] (22)
C_{max} (μg/mL)	19.3 (12)	25.1 (13)	19.0 (16)	28.6 (26)	(34.3, 19.6)	30.9 (14)
t_{max}[f] (h)	1.10 (0.98 – 21.00)	2.29 (1.00 – 21.83)	21.86 (19.80 – 26.10)	2.38 (1.00 – 26.40)	(22.37, 22.33)	1.05 (1.02 – 1.08)
$t_{1/2}$[g] (h)	44.2[e] (33.0 – 92.5)	63.4 (39.1 - 101)	83.2 (48.4 – 177)	114[a] (104 - 136)	NC	71.5 (38.4 – 90.0)
$C_{av,\tau}$ (μg/mL)	6.12[e] (38)	5.81 (35)	6.72 (61)	12.8[a] (14)	NC	14.0 (31)
$AUC_{(0-\infty)}$ (h·μg/mL)	1140[e] (53)	2010 (40)	2560 (80)	5000[a] (9)	NC	2990 (41)
$AUC_{(0-\tau)}$[h] (h·μg/mL)	1030[e] (38)	1950 (35)	2260 (61)	4310[a] (14)	NC	2350 (31)
CL (L/h)	0.0704[e] (27)	0.0493 (45)	0.0388 (77)	0.0232[a] (14)	NC	0.0425 (31)
V_{ss} (L)	4.50[e] (30)	4.28 (21)	5.23 (30)	3.91[a] (34)	NC	4.41 (16)
R_A	NC	NC	1.04[i,j] (35)	NC	NC	NC

Abbreviations: $AUC_{(0-\tau)}$, area under the concentration versus time curve from time zero to τ; $AUC_{(0-\infty)}$, area under the concentration versus time curve from time zero to ∞; C_{168h}, serum concentration collected 168 hours following the start of infusion; $C_{av,\tau}$, average serum concentration over dosing interval calculated using $AUC_{(0-\tau)}$; CL, total body clearance; C_{max}, maximum serum concentration; CV, coefficient of variation; h, hours; N, number of patients; NC, not calculable; Q2W, once every 2 weeks; QW, once weekly; RA, intrapatient accumulation ratio; $t_{1/2}$, terminal elimination half-life; t_{max}, time of maximum serum concentration; V_{ss}, volume of distribution at steady state.

[a]N = 3 patients; [b]N = 7 patients; [c]N = 4 patients; [d]N = 2 patients; reported as individual values; [e]N = 5 patients; [f]Median (Minimum, Maximum); [g]Geometric Mean (Minimum, Maximum); [h]τ = 168 h for WK1245 (data only available through Week 1) and QW regimens; τ = 336 h for Q2W regimen; [i]RA = AUC(0-τ),day 29/ AUC(0-τ),day 1; [j]N = 8 patients